AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2020
Jun 5, 2020
30849_dirs_2020-06-05_20de24a0-6242-4561-8079-24d6903d1945.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2020-06-05
Reporting Person: Foley Todd (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-06-05 | Common Stock | S | 1896 | $20.00 | Disposed | 2024893 | Indirect |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The shares were sold as follows: 1,825 by MPM BioVentures V, L.P. ("BV V") and 71 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F3: Shares are held as follows: 1,949,171 by BV V and 75,722 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.